1. Home
  2. NVAX vs NABL Comparison

NVAX vs NABL Comparison

Compare NVAX & NABL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVAX
  • NABL
  • Stock Information
  • Founded
  • NVAX 1987
  • NABL 2000
  • Country
  • NVAX United States
  • NABL United States
  • Employees
  • NVAX N/A
  • NABL N/A
  • Industry
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • NABL Computer Software: Prepackaged Software
  • Sector
  • NVAX Health Care
  • NABL Technology
  • Exchange
  • NVAX Nasdaq
  • NABL Nasdaq
  • Market Cap
  • NVAX 1.3B
  • NABL 1.5B
  • IPO Year
  • NVAX 1995
  • NABL N/A
  • Fundamental
  • Price
  • NVAX $8.60
  • NABL $8.23
  • Analyst Decision
  • NVAX Buy
  • NABL Buy
  • Analyst Count
  • NVAX 7
  • NABL 4
  • Target Price
  • NVAX $14.29
  • NABL $9.31
  • AVG Volume (30 Days)
  • NVAX 6.9M
  • NABL 749.6K
  • Earning Date
  • NVAX 11-11-2025
  • NABL 11-06-2025
  • Dividend Yield
  • NVAX N/A
  • NABL N/A
  • EPS Growth
  • NVAX N/A
  • NABL N/A
  • EPS
  • NVAX 2.54
  • NABL 0.01
  • Revenue
  • NVAX $1,078,718,000.00
  • NABL $482,397,000.00
  • Revenue This Year
  • NVAX $61.69
  • NABL $9.79
  • Revenue Next Year
  • NVAX N/A
  • NABL $8.97
  • P/E Ratio
  • NVAX $3.18
  • NABL $798.73
  • Revenue Growth
  • NVAX 9.22
  • NABL 7.40
  • 52 Week Low
  • NVAX $5.01
  • NABL $6.07
  • 52 Week High
  • NVAX $15.22
  • NABL $13.12
  • Technical
  • Relative Strength Index (RSI)
  • NVAX 60.46
  • NABL 55.23
  • Support Level
  • NVAX $7.83
  • NABL $8.10
  • Resistance Level
  • NVAX $8.31
  • NABL $8.45
  • Average True Range (ATR)
  • NVAX 0.37
  • NABL 0.23
  • MACD
  • NVAX 0.05
  • NABL 0.03
  • Stochastic Oscillator
  • NVAX 99.49
  • NABL 57.56

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

About NABL N-able Inc.

N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.

Share on Social Networks: